Samer Al Hadidi
Credentials | MD |
---|
| MS (CRDSA) |
---|
| FACP |
---|
| American Board of Internal Medicine |
---|
| American Board of Hematology |
---|
| American Board of Medical Oncology |
---|
| Michigan |
---|
| Texas |
---|
| Arkansas |
---|
Title | Assistant Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Internal Medicine, College of Medicine |
---|
Division | Hematology Oncology |
---|
Address | 12TH FLR ACRC 4301 W. Markham Mail Slot # 816 Little Rock AR 72205
|
---|
ORCID
.gif) | 0000-0003-4297-8042  |
---|
vCard | Download vCard |
---|
|
|
|
Overview Affiliation Biography Leader, The Foundation for the Accreditation of Cellular Therapy Accreditation Committee, University of Arkansas for Medical Sciences,Little Rock, Arkansas
Leader, Intake meeting, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas
University of Jordan, Amman, Jordan | MD | 06/2011 | Medicine | Michigan State University, Flint, MI | | 06/2016 | Internal Medicine residency | University of Michigan, Ann Arbor, MI | MS (CRDSA) | 05/2017 | Master of Science in Clinical Research and Statistical Analysis | Baylor College of Medicine, Houston, TX | | 06/2021 | Hematology and Medical Oncology | FDA-AACR | | 06/2021 | Drug Development oncology fellowship |
Research CAEL101-301 (AL HADIDI, SAMER)Jul 15, 2022 - Jul 14, 2033 Caelum Biosciences, Inc - Pass Through: IQVIA, Inc. A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients Role: Principal Investigator |
Outreach Bibliographic The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Netw Open. 2023 Nov 01; 6(11):e2342195. PMID: 37948080.
-
Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2023 Oct 26. PMID: 37883186.
-
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 Oct 17; 4(10):101214. PMID: 37794587.
-
Hussain M, Yellapragada S, Al Hadidi S. Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article. Blood Lymphat Cancer. 2023; 13:33-57. PMID: 37731771.
-
Wu C, Dongarwar D, Al Hadidi S. Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States. Clin Hematol Int. 2023; 5(4):1-9. PMID: 37752989.
-
Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023 Aug 31. PMID: 37646658.
-
Chakraborty R, Al Hadidi S, Cliff ERS, Mohyuddin GR. Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Adv. 2023 08 08; 7(15):3932-3935. PMID: 37196639.
-
Fahmawi S, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. J Cancer Policy. 2023 09; 37:100433. PMID: 37468042.
-
Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 Jul 11; 7(13):3069-3074. PMID: 36857755.
-
Ali MO, Abdullah HM, Obeidat K, Chakraborty R, Al Hadidi S. Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review. EJHaem. 2023 Aug; 4(3):719-722. PMID: 37601879.
-
Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 Jun 29; 16(1):70. PMID: 37386588.
-
Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757. PMID: 36827681.
-
Shrivastava T, Van Rhee F, Al Hadidi S. Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives. Onco Targets Ther. 2023; 16:441-464. PMID: 37359353.
-
Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498. PMID: 37282609.
-
Chakraborty R, Al Hadidi S. Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States. J Clin Oncol. 2023 07 10; 41(20):3657-3658. PMID: 37235838.
-
Abu Za'nouneh FJ, Ababneh O, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 May; 4(2):454-458. PMID: 37206288.
-
Mazahreh F, Al-Hader AA, Al Hadidi S. Visa Constraints and Career Choices for Oncologists. J Natl Compr Canc Netw. 2023 03; 21(3):332-334. PMID: 36898360.
-
Al Hadidi S, Dongarwar D, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, van Rhee F. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clin Hematol Int. 2023 Jun; 5(2-3):57-60. PMID: 36737587.
-
Al Hadidi S, Abu Zaid MI, Mustafa Ali M. Institutional disparities in the distribution of the American Society of Clinical Oncology grants. J Cancer Policy. 2023 03; 35:100404. PMID: 36649905.
-
Al Hadidi S, van Rhee F. Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial. J Clin Oncol. 2023 03 20; 41(9):1788. PMID: 36626704.
-
Al Hadidi S, Abuali I. The Inflation in Oncology Publications and Journals: A Vicious Cycle That Needs Immediate Attention. Cancer Invest. 2023 Jan 02; 1-7. PMID: 36592137.
-
Anampa-Guzm?n A, Alam ST, Abuali I, Al Hadidi S. Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review. Clin Hematol Int. 2023 Mar; 5(1):29-37. PMID: 36586086.
-
Al Hadidi S, Cliff ERS. CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma. Eur J Cancer. 2023 03; 182:1-2. PMID: 36680878.
-
Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 04; 58(4):443-445. PMID: 36550200.
-
Sawalha L, Kelkar AH, Mohyuddin GR, Goodman AM, Gagelmann N, Al Hadidi S. Analysis of repeated roles in editorial boards at oncology focused journals. J Cancer Policy. 2023 03; 35:100380. PMID: 36538988.
-
Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2023 03; 200(5):587-594. PMID: 36495317.
-
Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies F, Raab MS, Morgan G, Weinhold N. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022 11 22; 6(22):5873-5883. PMID: 35977111.
-
Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 12; 97(12):E451-E453. PMID: 36097868.
-
Hussain M, Khan F, Al Hadidi S. The use of bone-modifying agents in multiple myeloma. Blood Rev. 2023 01; 57:100999. PMID: 36050125.
-
Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877. PMID: 36018590.
-
Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022 08; 8:e2200119. PMID: 35960904.
-
Al Hadidi S, Dongarwar D, Salihu H, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clin Hematol Int. 2022 Sep; 4(3):117-120. PMID: 36131130.
-
Syaj S, Al-Kraimeen L, Akhdar M, Abushukair H, Mohty R, Al Hadidi S. Gender and Early-career Faculty Disparities in Hematology and Oncology Board Review Lecture Series. Blood Adv. 2022 Jul 27. PMID: 35894637.
-
Thalambedu N, Al Hadidi S. Thromboprophylaxis in multiple myeloma. Leuk Lymphoma. 2022 Dec; 63(12):2807-2815. PMID: 35759648.
-
Ali MO, Al Hadidi S. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Transplant Cell Ther. 2022 09; 28(9):572-580. PMID: 35750284.
-
Dweik A, Dweik H, Mian H, Mohan M, Schinke C, Al Hadidi S. Gender disparities in multiple myeloma publications. EJHaem. 2022 Aug; 3(3):966-969. PMID: 36051049.
-
Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA Oncol. 2022 06 01; 8(6):823-824. PMID: 35482363.
-
Ababneh O, Abushukair H, Qarqash A, Syaj S, Al Hadidi S. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenstr?m's Macroglobulinemia. Clin Hematol Int. 2022 Jun; 4(1-2):21-29. PMID: 35950210.
-
Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280. PMID: 35472167.
-
Abushukair H, Syaj S, Ababneh O, Qarqash A, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstr?m's Macroglobulinemia: A systematic review and meta-analysis. Am J Hematol. 2022 07; 97(7):942-950. PMID: 35358350.
-
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161. PMID: 35442451.
-
Hadidi SA. Melflufen in multiple myeloma: the conclusion matters. Lancet Haematol. 2022 04; 9(4):e244. PMID: 35358437.
-
Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 06 01; 97(6):E195-E198. PMID: 35285981.
-
Larsen K, Spencer H, Mohan M, Bailey C, Hill K, Kottarathara M, Parikh R, Hoque S, Erra A, Mitma AA, Mathur P, Yarlagadda L, Gundarlapalli S, Ogunsesan Y, Hussain M, Thalambedu N, Sehti J, Al Hadidi S, Thanendrarajan S, Graziutti M, Zangari M, Barlogie B, van Rhee F, Tricot G, Schinke C. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. J Clin Med. 2022 Mar 16; 11(6). PMID: 35329966.
-
Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16. PMID: 34775893.
-
Al Hadidi S, Kamble RT, Carrum G, Heslop HE, Ramos CA. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Adv. 2021 11 23; 5(22):4630-4633. PMID: 34461636.
-
Al Hadidi S, Yellapragada S. Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge? JAMA Oncol. 2021 10 01; 7(10):1449-1450. PMID: 34383000.
-
Nanah A, Al Hadidi S. Bing-Neel Syndrome: Update on the Diagnosis and Treatment. Clin Lymphoma Myeloma Leuk. 2022 03; 22(3):e213-e219. PMID: 34674984.
-
Al Hadidi S, Dongarwar D, Salihu HM, Kamble RT, Lulla P, Hill LC, Carrum G, Ramos CA, Heslop HE, Usmani SZ. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263. PMID: 34278937.
-
Awidi M, Al Hadidi S. Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions. JCO Oncol Pract. 2021 05; 17(5):265-271. PMID: 33974816.
-
Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to Treat High-Risk Myeloma at Diagnosis and Relapse. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:291-309. PMID: 34010042.
-
Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524. PMID: 33491524.
-
Al-Hadidi SA, Lee HJ. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma. JCO Oncol Pract. 2021 02; 17(2):64-71. PMID: 33434064.
-
Al Hadidi SA, Lee HJ. Pembrolizumab for the treatment of Hodgkin Lymphoma. Expert Opin Biol Ther. 2020 11; 20(11):1275-1282. PMID: 33006479.
-
Al-Hadidi SA, Chuang HH, Miranda RN, Lee HJ. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 02; 21(2):e105-e111. PMID: 33160934.
-
Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322. PMID: 32568574.
-
Al Hadidi S, Miller-Chism CN, Kamble R, Mims M. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e579-e589. PMID: 32409106.
-
Al Hadidi S, Udden M. Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia. Clin Case Rep. 2020 Jun; 8(6):1112-1113. PMID: 32577278.
-
Kyi HH, Zayed Y, Al Hadidi S. Ibrutinib-induced cardiomyopathy. J Community Hosp Intern Med Perspect. 2019; 9(1):50-52. PMID: 30788077.
-
Kheiri B, Osman M, Al Hadidi S. From a burn scar to malignancy! Marjolin's ulcer, a disease of wound neglect. Oxf Med Case Reports. 2018 Aug; 2018(8):omy044. PMID: 30151214.
-
Badami S, Upadhaya S, Velagapudi RK, Mikkilineni P, Kunwor R, Al Hadidi S, Bachuwa G. Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. J Oncol. 2018; 2018:6279871. PMID: 30112001.
-
Daher H, Towfiq B, Al Hadidi S. Gradually Worsening Pruritic Plaques. JAMA Oncol. 2018 Apr 01; 4(4):573-574. PMID: 29145542.
-
Al Hadidi S, Aburahma A, Badami S, Upadhaya S. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncol Res Treat. 2018; 41(4):226-235. PMID: 29562224.
-
Jarrah J, Samji V, Meshesha M, Kothuru C, Al Hadidi S. Methicillin-resistant Staphylococcus aureus prostatic abscess after traumatic rectal injury. Oxf Med Case Reports. 2018 Mar; 2018(3):omx111. PMID: 29593878.
-
Al Hadidi S. Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery. JAMA Oncol. 2018 02 01; 4(2):262. PMID: 28975199.
-
Al Hadidi S. Timing of Pregnancy and Survival in Women With Breast Cancer. JAMA Oncol. 2018 01 01; 4(1):131. PMID: 28880981.
-
Daher H, Al Hadidi S. Dysphagia lusoria presenting as epigastric pain. BMJ Case Rep. 2017 Dec 05; 2017. PMID: 29212867.
-
Al Hadidi S, Upadhaya S, Shastri R, Alamarat Z. Use of dictation as a tool to decrease documentation errors in electronic health records. J Community Hosp Intern Med Perspect. 2017; 7(5):282-286. PMID: 29147468.
-
Elounais F, Aburahma A, Alkotob ML, Al Hadidi S. Ventricular tachycardia after initiation of fingolimod. BMJ Case Rep. 2017 Sep 27; 2017. PMID: 28954755.
-
Badami S, Kyi HH, Upadhaya S, Al Hadidi S. Pancreatic Adenocarcinoma Masquerading as Idiopathic Chronic Pancreatitis with Delayed Diagnosis. Case Rep Oncol. 2017 Sep-Dec; 10(3):819-823. PMID: 29070996.
-
Al Hadidi S, Wu K, Aburahma A, Alamarat Z. Family with clots: antithrombin deficiency. BMJ Case Rep. 2017 Aug 11; 2017. PMID: 28801334.
-
Chughtai K, Gupta R, Upadhaya S, Al Hadidi S. Topical 5-Fluorouracil associated skin reaction. Oxf Med Case Reports. 2017 Aug; 2017(8):omx043. PMID: 28845237.
-
Alamarat Z, Onwuzurike N, Azher Q, Al Hadidi S. Huge teratoma in a teenager. Oxf Med Case Reports. 2017 Aug; 2017(8):omx040. PMID: 28852533.
-
Hadidi SA, Shastri R. Vanishing Lung Syndrome. J Am Osteopath Assoc. 2017 08 01; 117(8):541. PMID: 28759097.
-
Kyi HH, Aljariri Alhesan N, Upadhaya S, Al Hadidi S. Seizure Associated Takotsubo Syndrome: A Rare Combination. Case Rep Cardiol. 2017; 2017:8458054. PMID: 28811941.
-
Abdalla A, Bachuwa G, Al Hadidi S. A case of hypercalcemia with double pathology. J Community Hosp Intern Med Perspect. 2017 Jul; 7(3):178-181. PMID: 28808512.
-
Upadhaya S, Baig M, Towfiq B, Al Hadidi S. Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease. J Community Hosp Intern Med Perspect. 2017 Jul; 7(3):185-189. PMID: 28808514.
-
Osman M, Al Salihi M, Abu Sitta E, Al Hadidi S. A rare case of Epstein-Barr virus mucocutaneous ulcer of the colon. BMJ Case Rep. 2017 Jul 06; 2017. PMID: 28687701.
-
Al Hadidi S, Tareen K. Air in the portal vein: where computed tomography saved a patient's life. Oxf Med Case Reports. 2017 Apr; 2017(4):omx015. PMID: 28473923.
-
Al Hadidi S, Katato K, Bachuwa G. Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture. Case Rep Oncol. 2017 Jan-Apr; 10(1):272-275. PMID: 28512409.
-
Al Hadidi S. Aspirin and Cancer Risk. JAMA Oncol. 2016 10 01; 2(10):1371-1372. PMID: 27533744.
-
Al Hadidi S, Haddad RA, Abed F, Bachuwa G. Penile gangrene as a sign of uncontrolled diabetes mellitus. BMJ Case Rep. 2016 Feb 05; 2016. PMID: 26851255.
-
Al Hadidi S, Shaik Mohammed T, Bachuwa G. Unusual presentation of uterine leiomyoma. BMJ Case Rep. 2015 Apr 09; 2015. PMID: 25858937.
-
Al Hadidi S, Towfiq B, Bachuwa G. Dystextia as a presentation of stroke. BMJ Case Rep. 2014 Nov 20; 2014. PMID: 25414224.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2014 | 1 | 2015 | 1 | 2016 | 2 | 2017 | 14 | 2018 | 7 | 2019 | 1 | 2020 | 5 | 2021 | 9 | 2022 | 23 | 2023 | 21 |
To return to the timeline, click here.
|
Al Hadidi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|